Suppr超能文献

Toll样受体7介导非小细胞肺癌炎症消退及血管生成抑制

Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer.

作者信息

Liotti Federica, Marotta Maria, Sorriento Daniela, Pone Emanuela, Morra Francesco, Melillo Rosa Marina, Prevete Nella

机构信息

Institute of Experimental Endocrinology and Oncology (IEOS), CNR, 80131 Naples, Italy.

Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.

出版信息

Cancers (Basel). 2021 Feb 10;13(4):740. doi: 10.3390/cancers13040740.

Abstract

Pattern recognition receptors (PRR) promote inflammation but also its resolution. We demonstrated that a specific PRR-formyl peptide receptor 1 (FPR1)-sustains an inflammation resolution response with anti-angiogenic and antitumor potential in gastric cancer. Since toll-like receptor 7 (TLR7) is crucial in the physiologic resolution of airway inflammation, we asked whether it could be responsible for pro-resolving and anti-angiogenic responses in non-small cell lung cancer (NSCLC). TLR7 correlated directly with pro-resolving and inversely with angiogenic mediators in NSCLC patients, as revealed by a publicly available RNAseq analysis. In NSCLC cells, depletion of TLR7 caused an upregulation of angiogenic mediators and a stronger vasculogenic response of endothelial cells compared to controls, assessed by qPCR, ELISA, protein array, and endothelial cell responses. TLR7 activation induced the opposite effects. TLR7 silencing reduced, while its activation increased, the pro-resolving potential of NSCLC cells, evaluated by qPCR, flow cytometry, and EIA. The increased angiogenic potential of TLR7-silenced NSCLC cells is due to the lack of pro-resolving mediators. MAPK and STAT3 signaling are responsible for these activities, as demonstrated through Western blotting and inhibitors. Our data indicate that TLR7 sustains a pro-resolving signaling in lung cancer that inhibits angiogenesis. This opens new possibilities to be exploited for cancer treatment.

摘要

模式识别受体(PRR)既能促进炎症反应,也能促进炎症的消退。我们证明了一种特定的PRR——甲酰肽受体1(FPR1)——在胃癌中维持具有抗血管生成和抗肿瘤潜力的炎症消退反应。由于Toll样受体7(TLR7)在气道炎症的生理消退中起关键作用,我们不禁要问它是否也能引发非小细胞肺癌(NSCLC)的促消退和抗血管生成反应。一项公开的RNA测序分析显示,在NSCLC患者中,TLR7与促消退反应直接相关,与血管生成介质呈负相关。在NSCLC细胞中,通过qPCR、ELISA、蛋白质阵列和内皮细胞反应评估,与对照组相比,TLR7的缺失导致血管生成介质上调,内皮细胞的血管生成反应更强。TLR7激活则产生相反的效果。通过qPCR、流式细胞术和酶免疫分析评估,TLR7沉默降低了NSCLC细胞的促消退潜力,而其激活则增加了这种潜力。TLR7沉默的NSCLC细胞血管生成潜力增加是由于缺乏促消退介质。通过蛋白质印迹和抑制剂证明,MAPK和STAT3信号传导负责这些活动。我们的数据表明,TLR7在肺癌中维持一种抑制血管生成的促消退信号传导。这为癌症治疗开辟了新的可利用可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验